AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $73M
Founded date: 2001
Investors 3
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Prospect V... | prospectve... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.03.2021 | - | $20M | - |
| 04.05.2007 | - | $53M | - |
Mentions in press and media 7
| Date | Title | Description |
| 18.10.2022 | South Korea's LG Chem to invest US$566 million to acquire US Aveo Pharmaceuticals | SEOUL: South Korea's LG Chem said in a regulatory filing on Tuesday (Oct 18) that it is investing US$566 million to acquire US firm Aveo Pharmaceuticals Inc and enter the U.S. anti-cancer drug market. The deal is expected to close in the fi... |
| 04.11.2019 | AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20 | The FDA said that if the company wishes to proceed with a revised OS analysis in June 2020, it should submit an updated statistical analysis plan with a planned OS analysis based on the projected number of OS events – i.e. patient deaths – ... |
| 31.01.2019 | FDA stiff-arms Aveo on tivo, again; Sunovion Parkinson's drug rejected | → Aveo Oncology was hit with a fresh setback on Thursday. Its 2013-rejected tivozanib is still not ready for a new marketing application, the company said, citing FDA feedback. The agency recommended that the drug devel... |
| 23.06.2017 | Merck KGaA gets a thumbs up for once-dead MS drug; Aveo shares soar as tivo makes a comeback | → Cladribine is back. Once given up for dead by Merck KGaA, the multiple sclerosis drug has been endorsed by the CHMP in Europe, setting up a likely approval. Longtime Merck KGaA watchers will recall that Merck killed the p... |
| 04.05.2007 | Cancer-drug maker Aveo raises $53M | Aveo Pharmaceuticals, a Cambridge, Mass. cancer-drug company, raised $53 million in a fourth round of funding from a coalition of mostly blue-chip life-science investors. New investors included Biogen Idec, Bessemer Venture Partners, Merlin... |
| - | AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20 | The Food and Drug Administration has advised a biotech company not to seek approval just yet for its kidney cancer drug amid concerns over the results of one of its clinical trials. Cambridge, Massachusetts-based AVEO Oncology said Monday t... |
| - | AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility | BOSTON--(BUSINESS WIRE)--Mar 11, 2021-- AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: H... |